Subject
Endocrinology, Diabetes and Metabolism
Reference13 articles.
1. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study;Abou-Alfa;Lancet Oncol,2020
2. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements;Bekaii-Saab;Future Oncol,2020
3. Erdafitinib in locally advanced or metastatic urothelial carcinoma;Loriot;N Engl J Med,2019
4. Hyperphosphatemic tumoral calcinosis: pathogenesis, clinical presentation, and challenges in management;Boyce;Front Endocrinol (Lausanne),2020
5. Pan-FGFR inhibition leads to blockade of FGF23 signaling, soft tissue mineralization, and cardiovascular dysfunction;Yanochko;Toxicol Sci,2013
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献